Corvus Pharmaceuticals Inc (CRVS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Corvus Pharmaceuticals Inc (CRVS) has a cash flow conversion efficiency ratio of -0.043x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.37 Million) by net assets ($240.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Corvus Pharmaceuticals Inc to measure how many days the company can operate on defensive assets alone.
Corvus Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Corvus Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Corvus Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Corvus Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Azorim Investment Development and Construction Co Ltd
TA:AZRM
|
-0.301x |
|
Karelia Tobacco Company Inc
AT:KARE
|
0.022x |
|
Zhejiang Tony Electronic Co Ltd
SHG:603595
|
0.050x |
|
INVEX Controladora S.A.B. de C.V
MX:INVEXA
|
0.423x |
|
Beijing Oriental Jicheng Co Ltd
SHE:002819
|
0.017x |
|
Gr. Sarantis S.A.
AT:SAR
|
0.008x |
|
Haesung DS Co Ltd
KO:195870
|
0.049x |
|
Lingda Group Co Ltd
SHE:300125
|
-0.021x |
Annual Cash Flow Conversion Efficiency for Corvus Pharmaceuticals Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Corvus Pharmaceuticals Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Corvus Pharmaceuticals Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $61.20 Million | $-32.80 Million | -0.536x | +31.36% |
| 2024-12-31 | $32.57 Million | $-25.42 Million | -0.781x | -26.17% |
| 2023-12-31 | $38.68 Million | $-23.93 Million | -0.619x | -28.48% |
| 2022-12-31 | $56.12 Million | $-27.02 Million | -0.482x | -27.44% |
| 2021-12-31 | $97.16 Million | $-36.72 Million | -0.378x | +21.61% |
| 2020-12-31 | $72.15 Million | $-34.78 Million | -0.482x | +8.15% |
| 2019-12-31 | $71.11 Million | $-37.32 Million | -0.525x | -41.28% |
| 2018-12-31 | $110.34 Million | $-40.99 Million | -0.371x | +31.80% |
| 2017-12-31 | $84.83 Million | $-46.21 Million | -0.545x | -159.68% |
| 2016-12-31 | $132.80 Million | $-27.86 Million | -0.210x | -157.59% |
| 2015-12-31 | $-31.10 Million | $-11.33 Million | 0.364x | -44.70% |
| 2014-12-31 | $-159.00K | $-104.73K | 0.659x | -- |
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-cen… Read more